Experts suggest that enhancing the diets of prostate cancer patients may be a viable alternative to surgery. A recent international trial revealed that providing patients with supplements containing vegetables and beneficial bacteria helped slow down the progression of a key prostate cancer indicator in the blood. This approach could potentially assist patients in managing the anxiety associated with having a slow-growing tumor that may not pose a threat.
Patients with prostate cancer typically undergo regular prostate-specific antigen (PSA) blood tests to monitor tumor development, indicated by elevated PSA levels. In a study conducted by Bedfordshire University, men with slow-growing tumors were given a supplement consisting of broccoli, turmeric, pomegranate, green tea, ginger, and cranberry. Additionally, some participants received a probiotic supplement containing lactobacillus, a beneficial bacteria.
The trial results showed a significant slowdown in PSA progression in both groups, with greater improvement observed in those taking the probiotic supplement. This finding highlights the potential of diet-enhancing treatments, particularly for patients with slow-growing tumors that are under active surveillance by the NHS.
Professor Robert Thomas, the lead author of the study and a consultant clinical oncologist, emphasized the importance of dietary interventions in helping men remain on active surveillance and avoid unnecessary treatments. He noted that many patients opt for surgeries or chemotherapy due to uncertainties surrounding PSA spikes during routine testing, despite the fact that elevated PSA levels can have various causes other than prostate cancer.
The study also demonstrated that changes in PSA levels were supported by MRI scans, indicating the effectiveness of dietary supplements. While the results are promising, further follow-up is planned to assess the long-term impact of these supplements on reducing the need for major interventions like surgery or radiotherapy.
Although prostate cancer screening for high-risk men was rejected by UK regulators last year, the debate continues on the necessity of widespread screening. Routine PSA testing is not currently offered by the NHS, but individuals with potential prostate cancer symptoms may undergo testing. Supporters of screening argue that it should be extended to men at greater risk, including those with a family history of the disease and Black men over 50.
Despite differing opinions on screening, the challenges of managing prostate cancer diagnosis and treatment decisions persist. The decision-making process can be influenced by various factors, leading some patients to opt for treatment even when it may not be necessary. This highlights the importance of personalized medical approaches and ongoing research to improve patient outcomes in prostate cancer management.